Search

Your search keyword '"Clausen, Michael"' showing total 749 results

Search Constraints

Start Over You searched for: Author "Clausen, Michael" Remove constraint Author: "Clausen, Michael"
749 results on '"Clausen, Michael"'

Search Results

1. Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial

3. Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study

7. Risk of diabetes and the impact on preexisting diabetes in patients with lymphoma treated with steroid-containing immunochemotherapy

8. Effectiveness of R‐CHOP versus R‐CHOEP for treatment of young patients with high‐risk diffuse large B‐cell lymphoma: A Danish observational population‐based study.

10. Extended follow-up results beyond 2.5 years from the pivotal NHL-1 EPCORE trial: Subcutaneous epcoritamab monotherapy in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL).

11. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study

12. A Real‐World Data‐Based Analysis of Prognostic Indices as Part of Trial Eligibility Criteria in Diffuse Large B‐Cell Lymphoma Patients.

13. Walnut Allergy Across Europe: Distribution of Allergen Sensitization Patterns and Prediction of Severity

14. Real-world outcomes following third or subsequent lines of therapy:A Danish population-based study on 189 patients with relapsed/refractory large B-cell lymphomas

15. Risk of dementia among older patients with lymphoma:A Danish nationwide matched cohort study

16. Recommendations for asthma monitoring in children:A PeARL document endorsed by APAPARI, EAACI, INTERASMA, REG, and WAO

18. The role of trephine bone marrow biopsies in the era of measurable residual disease—Results from the CLL10 trial of the German CLL Study Group (GCLLSG).

19. Predictors of Food Sensitization in Children and Adults Across Europe

20. Prevalence of Food Sensitization and Food Allergy in Children Across Europe

22. Risk Factors for Hen's Egg Allergy in Europe: EuroPrevall Birth Cohort

23. Deep and Durable Responses with Epcoritamab SC Monotherapy in Patients with Relapsed or Refractory Follicular Lymphoma: Data from the Epcore NHL-1 Follicular Lymphoma Dose-Expansion Cohort

24. Patients in complete remission after R-CHOP(-like) therapy for diffuse large B-cell lymphoma have limited excess use of health care services in Denmark

25. Food Allergy in Adults: Substantial Variation in Prevalence and Causative Foods Across Europe

26. Revisiting beta‐2 microglobulin as a prognostic marker in diffuse large B‐cell lymphoma.

27. Recommendations for asthma monitoring in children: A PeARL document endorsed by APAPARI, EAACI, INTERASMA, REG, and WAO.

28. Real‐world outcomes following third or subsequent lines of therapy: A Danish population‐based study on 189 patients with relapsed/refractory large B‐cell lymphomas

32. ABCL-422 Subcutaneous Epcoritamab in Patients With Relapsed or Refractory Large B-Cell Lymphoma (EPCORE NHL-1): Pivotal Results from a Phase 2 Study

33. Treatment strategies and outcomes in diffuse large B-cell lymphoma among 1011 patients aged 75 years or older: A Danish population-based cohort study

34. Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma

36. POSTER: ABCL-517 Phase III Trial of Subcutaneous Epcoritamab + R-CHOP Versus R-CHOP Alone in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL): EPCORE DLBCL-2

37. ABCL-517 Phase III Trial of Subcutaneous Epcoritamab + R-CHOP Versus R-CHOP Alone in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL): EPCORE DLBCL-2

38. Oral Abstract: ABCL-500 Longer Follow-Up Reaffirms Subcutaneous Epcoritamab Induces Deep and Durable Complete Remissions in Patients With Relapsed/Refractory Large B-Cell Lymphoma: Updated Results From the Pivotal EPCORE NHL-1 Trial

39. ABCL-429 Epcoritamab + R-CHOP in Patients With Previously Untreated (1L) High-Risk Diffuse Large B-Cell Lymphoma, Including Double-Hit/Triple-Hit Lymphoma: Updated EPCORE NHL-2 Data

40. ABCL-500 Longer Follow-Up Reaffirms Subcutaneous Epcoritamab Induces Deep and Durable Complete Remissions in Patients With Relapsed/Refractory Large B-Cell Lymphoma: Updated Results From the Pivotal EPCORE NHL-1 Trial

41. POSTER: ABCL-500 Longer Follow-Up Reaffirms Subcutaneous Epcoritamab Induces Deep and Durable Complete Remissions in Patients With Relapsed/Refractory Large B-Cell Lymphoma: Updated Results From the Pivotal EPCORE NHL-1 Trial

42. POSTER: ABCL-429 Epcoritamab + R-CHOP in Patients With Previously Untreated (1L) High-Risk Diffuse Large B-Cell Lymphoma, Including Double-Hit/Triple-Hit Lymphoma: Updated EPCORE NHL-2 Data

43. P1118: LONGER FOLLOW-UP FROM THE PIVOTAL EPCORE NHL-1 TRIAL REAFFIRMS SUBCUTANEOUS EPCORITAMAB INDUCES DEEP, DURABLE COMPLETE REMISSIONS IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA

44. P1676: RISK OF DEMENTIA IN OLDER PATIENTS TREATED WITH CHEMOTHERAPY FOR LYMPHOMA: A DANISH NATIONWIDE COHORT STUDY

45. P1116: HIGH COMPLETE METABOLIC RESPONSE RATES WITH EPCORITAMAB + R-CHOP IN PREVIOUSLY UNTREATED (1L) PATIENTS WITH HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA, INCLUDING DOUBLE/TRIPLE-HIT: EPCORE NHL-2 UPDATE

46. The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy

47. Real‐world outcomes following third or subsequent lines of therapy: A Danish population‐based study on 189 patients with relapsed/refractory large B‐cell lymphomas.

48. Phase 3 trial of subcutaneous epcoritamab + R-CHOP versus R-CHOP in patients (pts) with newly diagnosed diffuse large B-cell lymphoma (DLBCL): EPCORE DLBCL-2.

49. Deep learning-based algorithm accurately classifies sleep stages in preadolescent children with sleep-disordered breathing symptoms and age-matched controls

50. Work Disability and Return to Work After Lymphoma: A Danish Nationwide Cohort Study

Catalog

Books, media, physical & digital resources